Month: October 2017
Anthem, one of the nation’s major health insurance companies, said on Wednesday that it planned to start its own business to manage prescription drug plans by partnering with CVS Health, the large pharmacy benefit manager and drugstore chain.
President Trump signed an executive order on Thursday morning that he said would begin “saving the American people from the nightmare of Obamacare.” On Thursday evening, he announced he would stop making scheduled payments to insurance companies that help them lower deductibles for low-income customers. There’s a lot that’s still uncertain about how the two actions will change the health law. Here’s what we know so far.
A pair of leading Republican and Democratic senators reached an agreement Tuesday to fund key federal health-care subsidies that President Trump ended last week — and the president expressed support for the plan.
Facing a Sunday deadline to approve or reject measures passed by the legislature this year, Brown weighed in on some key health care bills, including measures to protect Californians who buy insurance for themselves.
In an aggressive move to dismantle Obamacare, President Trump announced Thursday that the government was ending payments to health insurers that help fund the law.
California Attorney General Xavier Becerra said Friday he will sue the Trump administration for halting billions of dollars in federal payments to health insurers that help low-income Americans afford health care under the Affordable Care Act.
President Trump on Monday attacked prescription drug companies and hinted at taking action to bring down rising drug prices.
The Women’s Choice Award, one of America’s most trusted referral sources for brands and services, distributed a statewide survey to more than 10,000 women who reside in California. Those women were asked to identify which health insurance plan they would highly recommend to their families and friends. Kaiser Permanente was the clear winner, garnering a significant majority of the vote.
President Donald Trump isn’t done talking about U.S. drug prices, and investors aren’t done worrying about what he might do.
Negotiations on a bipartisan bill to fund the popular Children's Health Insurance Program (CHIP) have made little progress, a top House Republican said Monday.